Re: introduction to OA of pharmacogenomics in product labeling

Dear Richard,
The first thing I notice right away are the OA definitions as
AnnotationProperty such as:
<AnnotationProperty rdf:about="&oa;annotatedBy"/>
While they are defined as ObjectProperties in OA:
http://www.w3.org/ns/oa#objectproperties

The SpecificResources and Selector seems accurate.

The 'annotation sets' like '&poc;pharmgx-spl-annotation-set-7'
seems very similar of what I was doing in Annotation Ontology with
ao:AnnotationSet:
http://code.google.com/p/annotation-ontology/wiki/v2AnnotationSets
Was oa:onResource -> ao;onResource and oa:item -> ao:item?
oa:onResource is not a Open Annotation term and oa:item is currently used
for different constructs.

We did not include anything to organize annotation in the current specs.
In Domeo and I still use the oa:AnnotationSet in combination with Open
Annotation.
In other words exactly the way you did it but with namespace ao (annotation
ontology).

Other options are ORE [http://www.openarchives.org/ore/] or Collections
Ontology [http://code.google.com/p/collections-ontology/wiki/StructureSet]

Anybody has comments on this?

<NamedIndividual rdf:about="&poc;pharmgx-spl-annotation-set-8">
        <rdf:type rdf:resource="http://purl.org/dc/dcmitype/Collection"/>
        <oa:annotatedAt rdf:datatype="&xsd;date">2013-03-14</oa:annotatedAt>
        <oa:annotatedBy>TRIADS Lab, University of
Pittsburgh</oa:annotatedBy>
        <oa:onResource
rdf:resource="file:///home/rdb20/Downloads/d2rq-0.8.1/linkedSPLs-dump.nt#structuredProductLabelMetadata/cb684ad9-0b72-406f-8a07-a419254ccd36"/>
        <oa:item rdf:resource="&poc;pharmgx-spl-annotation-item-10"/>
        <oa:item rdf:resource="&poc;pharmgx-spl-annotation-item-16"/>
    </NamedIndividual>



Best,
Paolo







On Fri, Mar 15, 2013 at 9:57 AM, Richard Boyce <rdb20@pitt.edu> wrote:

>  Dear Open Annotators,
>
> My name is Rich Boyce, I am an Assistant Professor at the University of
> Pittsburgh Department of Biomedical Informatics. I have been following the
> work of this group for awhile because and am interested in applying Open
> Data Annotation to my research on medication safety. This email is to
> notify the group of a new resource that I have created using the most
> recent Open Data Annotation guidelines. I am seeking feedback on the
> resource from an Open Data Annotation perspective since the guidelines are
> so fresh and this is my first attempt at developing a resource using them.
>
> Currently, I am leading a project that involves annotating
> pharmacogenomics statements in United States product labeling. Drug product
> labels are available in electronic form from the DailyMed website [1] and
> the FDA has created indexed product labels sections that make some
> statement about a pharmacogenomics biomarker [2]. Pharmacists have several
> use cases for the product label statements and find this indexing approach
> unsatisfactory. To address this issue, a team of pharmacists at the U of
> Pittsburgh are annotating the indexed statements using a new semantic model
> [3]. This past week, I  created an RDF data set [4] following the Open Data
> Annotation guidelines [5] for ~140 annotations that are undergoing final
> validation. Would anyone be interested in reviewing this data set and
> letting me know if it seems to follow the guidelines as intended?
>
> Kind regards,
> -Rich Boyce
>
> Richard D Boyce, PhD
> Assistant Professor of Biomedical Informatics
> Faculty, Geriatric Pharmaceutical Outcomes and Gero-Informatics Research and Training Program
> Scholar, Comparative Effectiveness Research Program
> University of Pittsburghrdb20@pitt.edu
> Office: 412-648-9219
> Twitter: @bhaapgh
>
>
>
> 1. dailymed.nlm.nih.gov
>
> 2.
> http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm
>
> 3. Boyce, RD., Freimuth, RR., Romagnoli, KM., Pummer, T., Hochheiser, H.,
> Empey, PE. Toward semantic modeling of pharmacogenomic knowledge for
> clinical and translational decision support. Proceedings of the 2013 AMIA
> Summit on Translational Bioinformatics. San Francisco, March 2013.
>
> 4.
> https://code.google.com/p/swat-4-med-safety/source/browse/trunk/analyses/pharmgx-statement-annotation/data/all-NON-VALIDATED-annotations-from-092012-BETA-OA-model-03142013.xml
>
> 5. http://www.openannotation.org/spec/core/
>
> --
>
>


-- 
Dr. Paolo Ciccarese
http://www.paolociccarese.info/
Biomedical Informatics Research & Development
Instructor of Neurology at Harvard Medical School
Assistant in Neuroscience at Mass General Hospital
Member of the MGH Biomedical Informatics Core
+1-857-366-1524 (mobile)   +1-617-768-8744 (office)

CONFIDENTIALITY NOTICE: This message is intended only for the addressee(s),
may contain information that is considered
to be sensitive or confidential and may not be forwarded or disclosed to
any other party without the permission of the sender.
If you have received this message in error, please notify the sender
immediately.